BiotechTube

Hetrombopag Olamine+Standard Therapy + Placebo+Standard Therapy

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Severe Aplastic Anemia

Conditions

Severe Aplastic Anemia

Trial Timeline

Mar 5, 2019 → Jul 3, 2024

NCT ID
NCT03825744

About Hetrombopag Olamine+Standard Therapy + Placebo+Standard Therapy

Hetrombopag Olamine+Standard Therapy + Placebo+Standard Therapy is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Severe Aplastic Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03825744. Target conditions include Severe Aplastic Anemia.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT03825744Phase 3Completed

Competing Products

20 competing products in Severe Aplastic Anemia

See all competitors
ProductCompanyStageHype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
80
Drotrecogin alfa (activated)Eli LillyPhase 2
52
CT-P13 SC Auto-Injector + Placebo Auto-InjectorCelltrionPhase 3
77
CT-P17 + EU-approved HumiraCelltrionPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
CS-3150Daiichi SankyoPhase 3
77
tacrolimusAstellas PharmaApproved
85
enzalutamideAstellas PharmaPhase 1
33
Isavuconazonium Injection [Cresemba] + PlaceboAstellas PharmaPhase 3
77
AlefaceptAstellas PharmaApproved
85
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)Sun PharmaceuticalPhase 2
52
Tildrakizumab 100 mg + PlaceboSun PharmaceuticalPhase 3
77
Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + PlaceboSun PharmaceuticalPhase 2/3
65
CefiderocolShionogiApproved
85
eritoran tetrasodium + PlaceboEisaiPhase 3
77
Donepezil HClEisaiApproved
85
Donepezil Hydrochloride (Aricept)EisaiApproved
85
KHK4827 + PlaceboKyowa KirinPhase 3
77

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85